Tafasitamab plus rituximab for PTLD after solid organ transplant
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial studies tafasitamab plus rituximab to treat a type of lymphoma called post-transplant lymphoproliferative disorder (PTLD) in adults after a solid organ transplant. It’s aimed at helping stop the PTLD when it can be measured and before you’ve had PTLD treatment beyond limited measures like steroid or reducing anti-rejection drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign consent (and allow your health information to be used).
- Have PTLD that started after a solid organ transplant (heart, lung, liver, kidney, pancreas, or small intestine).
- Your PTLD tumor must be confirmed by biopsy/resection and is a B-cell type that has CD19 and CD20, with or without an EBV (virus) link.
- Have measurable disease (a tumor larger than 1.5 cm) and/or involvement in bone marrow.
- No prior PTLD treatment with chemotherapy or other cancer drugs (radiation, steroids, antivirals, and reducing anti-rejection medicines are allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether doing your own stem cell transplant, followed by polatuzumab, can improve outcomes in people with specific B-cell non-Hodgkin or Hodgkin lymphomas that did not fully respond or has come back. It aims to add a targeted medicine after transplant to help control the lymphoma.
This study tests a combination of two medications, loncastuximab tesirine and rituximab, as the first treatment for a type of lymphoma that can develop after an organ transplant. The goal is to see if this combination is safe and effective at shrinking or eliminating the cancer.
This trial tests whether a drug called rituximab can prevent a type of cancer called PTLD in people who have had an organ transplant and are showing signs of an EBV infection. EBV is a common virus that can be more dangerous for transplant patients, and this study aims to see if using rituximab early can stop PTLD from developing.
This trial tests a combination of three drugs (tafasitamab, lenalidomide, and rituximab) for people with newly diagnosed follicular or marginal zone lymphoma who have not had treatment before. The goal is to see if this combination works well and is safe.
This trial tests combining two drugs (rituximab and tafasitamab) with donor natural killer (NK) cells to treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatments. The goal is to see if this combination can help the immune system fight the cancer more effectively.
This study tests a drug called epcoritamab for people who have a type of lymphoma that developed after an organ transplant and has not responded to standard treatment. The drug aims to help your immune system fight the cancer cells.
Hear when a new Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.